Biomarkers and Surrogate Endpoints in Renal Transplantation: Present Status and Considerations for Clinical Trial Design
Peter A. Lachenbruch(Center for Biologics Evaluation and Research), Robert B. Colvin(Harvard University), Ezio Bonvini(MacroGenics (United States)), M Cavaillé‐Coll(Center for Drug Evaluation and Research), Amy S. Rosenberg(Center for Drug Evaluation and Research)
Cited by 73
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k